MA49700A - Procédé amélioré pour la préparation de dérivés d'aminopyrimidine - Google Patents

Procédé amélioré pour la préparation de dérivés d'aminopyrimidine

Info

Publication number
MA49700A
MA49700A MA049700A MA49700A MA49700A MA 49700 A MA49700 A MA 49700A MA 049700 A MA049700 A MA 049700A MA 49700 A MA49700 A MA 49700A MA 49700 A MA49700 A MA 49700A
Authority
MA
Morocco
Prior art keywords
preparation
improved process
aminopyrimidine derivatives
aminopyrimidine
derivatives
Prior art date
Application number
MA049700A
Other languages
English (en)
Other versions
MA49700B1 (fr
Inventor
Yoon-Ah Hwang
Hyun Ju
Ja-Heouk Khoo
Seong-Ran Lee
Jong-Chul Lim
Sang-Ho Oh
Dae-Gyu Park
su-min Park
Woo-Seob Shin
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MA49700A publication Critical patent/MA49700A/fr
Publication of MA49700B1 publication Critical patent/MA49700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
MA49700A 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride MA49700B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (fr) 2017-07-28 2018-07-25 Procédé amélioré pour la préparation de dérivés d'aminopyrimidine

Publications (2)

Publication Number Publication Date
MA49700A true MA49700A (fr) 2021-03-17
MA49700B1 MA49700B1 (fr) 2023-09-27

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49700A MA49700B1 (fr) 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride

Country Status (32)

Country Link
US (4) US10889578B2 (fr)
EP (1) EP3658552B1 (fr)
JP (2) JP7228562B2 (fr)
KR (1) KR102688084B1 (fr)
CN (2) CN116987112B (fr)
AU (2) AU2018308038B2 (fr)
BR (1) BR112020001278A2 (fr)
CA (1) CA3070069C (fr)
CO (1) CO2020000374A2 (fr)
DK (1) DK3658552T3 (fr)
EA (1) EA202090383A1 (fr)
ES (1) ES2962961T3 (fr)
FI (1) FI3658552T3 (fr)
HR (1) HRP20231191T1 (fr)
HU (1) HUE063533T2 (fr)
IL (2) IL271973B (fr)
LT (1) LT3658552T (fr)
MA (1) MA49700B1 (fr)
MD (1) MD3658552T2 (fr)
MX (2) MX393995B (fr)
MY (1) MY198379A (fr)
PH (1) PH12020500059A1 (fr)
PL (1) PL3658552T3 (fr)
PT (1) PT3658552T (fr)
RS (1) RS64654B1 (fr)
SA (2) SA520411112B1 (fr)
SG (1) SG11201913517UA (fr)
SI (1) SI3658552T1 (fr)
SM (1) SMT202300339T1 (fr)
UA (1) UA125317C2 (fr)
WO (1) WO2019022485A1 (fr)
ZA (1) ZA202001250B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393995B (es) 2017-07-28 2025-03-24 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CN116199701A (zh) * 2023-02-27 2023-06-02 安徽中医药大学 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (fr) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Méthodes pour traiter le cancer du poumon non à petites cellules
WO2026042017A1 (fr) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab en association avec le lazertinib pour le traitement du cancer du poumon non à petites cellules (cpnpc)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
PL370137A1 (en) 2001-11-27 2005-05-16 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
EP2222647B1 (fr) 2006-10-23 2015-08-05 Cephalon, Inc. Dérives bicycliques fusionnes de 2,4-diaminopyrimidine utilises comme inhibiteurs de alk et c-met
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
BR112012008677A2 (pt) 2009-10-12 2018-03-20 Myrexis Inc compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon
JP5740409B2 (ja) * 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
KR101851130B1 (ko) 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
EP3170813B1 (fr) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Dérivés de benzimidazole comme inhibiteurs de pi3 kinase
WO2012061303A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
JP5868996B2 (ja) 2010-12-13 2016-02-24 アレイ バイオファーマ、インコーポレイテッド ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物
EP2736895B1 (fr) * 2011-07-27 2016-01-06 Astrazeneca AB Deruves de 2-(2,4,5-substituted-anilino) pyrimidine comme modulatuers du egfr utiles dans le traitement du cancer
WO2013096642A1 (fr) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
RS59420B1 (sr) 2011-12-30 2019-11-29 Hanmi Pharmaceutical Co Ltd Derivati tieno[3,2-d]pirimidina sa inhibitornom aktivnošću za proteinske kinaze
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN106660993B (zh) 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
MX393995B (es) 2017-07-28 2025-03-24 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina
DK3658553T3 (da) 2017-07-28 2022-07-25 Yuhan Corp Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf
CN111295381A (zh) 2017-07-28 2020-06-16 株式会社柳韩洋行 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
IL271973B (en) 2022-08-01
JP7539451B2 (ja) 2024-08-23
RS64654B1 (sr) 2023-10-31
JP2020528440A (ja) 2020-09-24
IL292429A (en) 2022-06-01
US20210269427A1 (en) 2021-09-02
HRP20231191T1 (hr) 2024-02-02
ES2962961T3 (es) 2024-03-22
PH12020500059A1 (en) 2020-09-28
ZA202001250B (en) 2023-04-26
AU2022202936B2 (en) 2023-04-27
SA520411112B1 (ar) 2022-02-21
EP3658552A4 (fr) 2021-06-23
US20230312545A1 (en) 2023-10-05
CA3070069A1 (fr) 2019-01-31
MX2022008743A (es) 2023-02-02
CN116987112A (zh) 2023-11-03
SA522431428B1 (ar) 2024-10-21
MX393995B (es) 2025-03-24
US20220281861A1 (en) 2022-09-08
BR112020001278A2 (pt) 2020-07-21
AU2018308038A1 (en) 2020-01-30
AU2018308038B2 (en) 2022-02-03
CN111315742A (zh) 2020-06-19
FI3658552T3 (fi) 2023-11-16
IL292429B1 (en) 2023-05-01
EP3658552B1 (fr) 2023-09-13
US11286253B2 (en) 2022-03-29
HUE063533T2 (hu) 2024-01-28
EP3658552A1 (fr) 2020-06-03
IL292429B2 (en) 2023-09-01
EA202090383A1 (ru) 2020-06-15
UA125317C2 (uk) 2022-02-16
DK3658552T3 (da) 2023-11-20
CA3070069C (fr) 2024-02-20
WO2019022485A1 (fr) 2019-01-31
AU2022202936A1 (en) 2022-05-26
IL271973A (en) 2020-02-27
JP2023027091A (ja) 2023-03-01
US10889578B2 (en) 2021-01-12
NZ761156A (en) 2024-01-26
PT3658552T (pt) 2023-11-03
CN111315742B (zh) 2023-09-01
KR20190013553A (ko) 2019-02-11
LT3658552T (lt) 2023-11-27
US20200165236A1 (en) 2020-05-28
MY198379A (en) 2023-08-28
US12187714B2 (en) 2025-01-07
MA49700B1 (fr) 2023-09-27
JP7228562B2 (ja) 2023-02-24
PL3658552T3 (pl) 2024-02-19
MD3658552T2 (ro) 2024-02-29
SI3658552T1 (sl) 2023-11-30
KR102688084B1 (ko) 2024-07-24
CO2020000374A2 (es) 2020-05-05
SG11201913517UA (en) 2020-02-27
SMT202300339T1 (it) 2023-11-13
CN116987112B (zh) 2025-12-19
US11708362B2 (en) 2023-07-25

Similar Documents

Publication Publication Date Title
EP3658552A4 (fr) Procédé amélioré pour la préparation de dérivés d'aminopyrimidine
EP3677589A4 (fr) Procédé amélioré de production d'un conjugué anticorps-médicament
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
EP3448918A4 (fr) Procédé de préparation de résines d'organopolysiloxane
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
MA51988A (fr) Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
EP3683205A4 (fr) Procédé de préparation d'isocyanate aliphatique
MA49703A (fr) Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
EP3606533A4 (fr) Procédé de préparation de dérivés sulfonylcarbamate d'acides biliaires
MA45768A (fr) Procédé pour la préparation de compositions d'immunoglobulines
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP3431520A4 (fr) Procédé de préparation d'un copolymère d'oxyméthylène
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
EP4021920A4 (fr) Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
MA51510A (fr) Procédés de préparation de dérivés d'indolinobenzodiazépine
EP3663322A4 (fr) Procédé de préparation d'oligomère de butène
EP3354701A4 (fr) Procédé de préparation d'une composition de revêtement par électrodéposition cationique
EP3314001A4 (fr) Procédés et compositions pour la préparation d'éphédrine et de composés alcaloïdes apparentés
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3436439A4 (fr) Procédé de préparation de dérivés de diphénylpyrazine